Dosimetric comparison of VitalBeam® and Halcyon™ 2.0 for hypofractionated VMAT with simultaneous integrated boost treatment of early-stage left-sided breast cancer

Eunbin Ju1,2 | Eun Jeong Heo1,2 | Chun Gun Park3 | Minseok Kim4 | Kwang Hyeon Kim5 | Jang Bo Shim6 | Young Je Park1 | Nam Kwon Lee1 | Chul Yong Kim1 | Suk Lee1

1 Department of Radiation Oncology, College of Medicine, Korea University, Seoul, Korea
2 Department of Bio-Medical Science, Graduate School of Korea University, Sejong, Korea
3 Department of Mathematics, Kyonggi University, Gyeonggi, Korea
4 Department of Biostatistics and Computing, Yonsei University Graduate school, Seoul, Korea
5 Department of Neurosurgery, Ilsan Paik Hospital, College of Medicine, Inje University, Goyang, Korea
6 Department of Radiation Oncology, Guro Hospital, Korea University Medical Center, Seoul, Korea

Correspondence
Suk Lee, Department of Radiation Oncology, College of Medicine, Korea University, 126-1, 5-Ga Anam-dong, Sungbuk-Gu, Seoul 02941, Korea.
Email: sukmp@korea.ac.kr

Abstract
Purpose: This study compared the quality of treatment plans for early-stage, left-sided breast cancer, as planned for and delivered by the Halcyon™ and VitalBeam®.

Materials and methods: Fifteen patients diagnosed with early-stage left-sided breast cancer, who had received VMAT with hypofractionated SIB, were recruited. All cases were planned using Halcyon™ comprising a dual-layer MLC (DL-MLC) and VitalBeam® with a Millennium 120 MLC (VB-MLC). For the PTVs, the quality of coverage (QC), conformity index (CI), and homogeneity index (HI) were calculated for each plan. The dosimetric differences between the two treatment plans were statistically compared using the Wilcoxon signed-rank test (p < 0.05). To evaluate delivery efficiency, the average delivery time for each patient’s treatment plan was recorded and compared.

Results: For the PTVs, the two plans (DL-MLC and VB-MLC) were comparable in terms of the QC, CI, and HI. However, \( V_{30\text{Gy}} \) and \( D_{\text{mean}} \) for the heart in the DL-MLC plan were significantly reduced by 0.49% and 14.6%, respectively, compared with those in the VB-MLC plan (p < 0.05). The \( D_{\text{mean}} \) value for the ipsilateral lung in the DL-MLC plan significantly decreased by 5.5%, compared with that in the VB-MLC plan (p < 0.05). In addition, the delivery times for the DL-MLC and VB-MLC plans were 79 ± 10 and 101 ± 11 s, respectively.

Conclusions: DL-MLC plans were found to improve OAR sparing. In particular, when treating left-sided breast cancer via DL-MLC plans, the risk of heart toxicity is expected to be reduced.

Keywords
dosimetric comparison, Halcyon™, left-sided breast cancer, VitalBeam®

1 INTRODUCTION

Breast cancer is the most commonly diagnosed cancer in women worldwide. The American Cancer Society estimated that there were 2 261 410 new female breast cancer cases in 2020, accounting for 11.7% of the total cancer cases in 2020.1 The recent decline in breast cancer mortality rates might be attributed to early detection with mammography, adjuvant systemic therapies, and regional radiotherapy.2 Radiotherapy after

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine
breast-conserving surgery not only substantially reduces the risk of local recurrence, but also moderately reduces the risk of death from breast cancer and increases long-term survival compared with mastectomy or lumpectomy alone.

After breast-conserving therapy, dose escalation with the addition of a boost to the tumor bed could reduce local recurrence; however, it extends the duration of treatment and increases the risk of breast fibrosis. Nevertheless, the simultaneous integrated boost (SIB) technique, whereby doses are delivered at a high dose per fraction to the tumor bed, leads to minimization of the overall treatment time. This technique also has several dosimetric benefits regarding dose conformity to the target and reduction of dose per fraction to organs at risk (OARs). Furthermore, advanced radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) improve the target coverage while exposing OARs to lower dose volumes.

Radiation exposure of the lungs is unavoidable when irradiating breasts with or without regional lymph nodes, and increases the risk of pulmonary radiation toxicity, such as the risk of radiation-induced pneumonitis and pulmonary fibrosis. Furthermore, presumably through incidental irradiation of the heart, the risk of ischemic heart disease can be increased by radiotherapy. Thus, when treating breast cancer, it is crucial to reduce incidental doses to the heart and lungs using modern radiotherapy techniques. These efforts could lead to a reduction in the risk of radiation-induced toxicity.

The linear accelerator called Halcyon that features the MLC was introduced by Varian Medical Systems (Palo Alto, CA). This system features a dual-layer stacked and staggered MLC with a 1-cm leaf width in each layer and is configured to simultaneously provide sufficient beam modulation and attenuation. Although it has larger leaf widths than the Millennium 120 MLC, Halcyon has an increased gantry speed, leaf speed, and decreased dosimetric leaf gap (DLG) compared with Vital-Beam (Varian Medical Systems, Palo Alto, CA, USA). This study compared the quality of treatment plans for early-stage, left-sided breast cancer, as planned for and delivered by the Halcyon and VitalBeam.

### 2 MATERIALS AND METHODS

#### 2.1 Patient characteristics

Fifteen patients, who were diagnosed with early-stage left-sided breast cancer and had been treated with VMAT-hypofractionated SIB technique with VitalBeam after conservative breast surgery from our institution, were included in this study. The study was conducted between January 2018 and January 2019.

#### 2.2 Treatment systems

The mechanical characteristics of the Halcyon and VitalBeam treatment systems are shown in Table 1 in detail. VitalBeam is configured with multiphoton beam energy (6 MV, 10 MV, 6 MV-FFF). The Millennium 120 MLC system used in VitalBeam features the MLC speed of 2.5 cm/s and transmission of 1.36%. The system with gantry speed is 1 rpm.

Halcyon is a ring-type radiation treatment delivery system that offers only a 6-MV flattening-filter-free (FFF) photon beam with the maximum dose rate of 800 MU/min. The omission of a flattening filter provides a higher dose rate and lower average energy than that of a 6-MV photon beam flattened with a filter. Another feature of Halcyon is the new dual-layer stacked MLC system with the speed of 5.0 cm/s, which is faster than the speed of the Millennium 120 MLC. This DL-MLC design with faster MLC speed significantly reduces the leakage and transmission: 0.01% transmission for the DL-MLC compared with 1.36% for the Millennium 120 MLC.

#### 2.3 Planning condition

CT scans were acquired under free breathing using a Big Bore CT scanner (Philips Healthcare, Cleveland, OH, USA). The clinical target volume (CTV) delineation was performed by physicians based on the ESTRO consensus guideline. The planning target volume (PTV) was defined with the CTV expansion of 5 mm and cropped by 5 mm inside the patient outline to exclude the derma region. The boost volume was defined according to the surgical bed, determined by adding 1 cm to the surgical clips placed in the lumpectomy cavity during surgery.

VB-MLC plans were originally established and DL-MLC plans were retrospectively established in the Eclipse TPS (version 15.6; Varian Medical Systems, Palo Alto, CA, USA) using the same planning condition (Table 2). The same isocenter was used across the two systems. The prescription dose was 4256 cGy for the PTV, with a 266 cGy daily dose and 5248 cGy for the integrated boost volume, with the daily dose of 328 cGy. All plans were optimized using the Eclipse photon optimization algorithm, and calculated using an analytic anisotropic algorithm, to deliver at least 95%–105% of the prescribed dose to the targets.

The considered OARs were the heart, ipsilateral and contralateral lungs, and the contralateral breast. The dose constraints were established based on our institutional guidelines (heart $V_{30Gy} < 5\%$, $D_{mean} < 500$ cGy; contralateral breast $D_{mean} < 300$ cGy; ipsilateral lung $D_{mean} < 1000$ cGy; contralateral lung $D_{mean} < 200$ cGy; whole lung $V_{20Gy} < 15\%$, $D_{mean} < 800$ cGy).
TABLE 1 Mechanical characteristics of Halcyon™ and VitalBeam®

| Parameter                        | Halcyon™                      | VitalBeam®                   |
|----------------------------------|-------------------------------|------------------------------|
| Photon energy                    | 6 MV FFF only                 | 6, 10 MV, 6 MV FFF           |
| Maximum field size               | 28 cm × 28 cm                 | 40 cm × 40 cm                |
| MLC design                       | Dual-layer MLC                | 120 MLC                      |
| Leaf width (effective leaf width) | 10 mm (5 mm)                  | 5 mm (5 mm)                  |
| DLG                              | 0.01 mm                       | 0.5 mm                       |
| MLC speed                        | 5.0 cm/s                      | 2.5 cm/s                     |
| Gantry speed                     | 4 rpm                         | 1 rpm                        |
| Nominal 6FFF transmission        | Single-layer: 0.47%           | Dual-layer: 0.01%            |

DLG, dosimetric leaf gap; FFF, flattening-filter-free.; MLC, multileaf collimator.

TABLE 2 Treatment planning conditions applied to both Halcyon™ and VitalBeam®

| Parameter                        | Value | Photon energy | Prescription dose (PTV) | Prescription dose (Boost) | Fractions | Coll. Angle |
|----------------------------------|-------|---------------|-------------------------|---------------------------|-----------|-------------|
|                                  |       | 6 FFF         | 4256 cGy                | 5248 cGy                  | 16 fr     | 140–300 (2 arc) |

PTV, planning target volume.

2.4 Evaluation of plan quality and delivery time

In terms of the PTV, the quality of coverage (QC), conformity index (CI), and homogeneity index (HI) were evaluated for the treatment plans, as described in Table 3.22,23

For OAR sparing, heart V30Gy, heart mean dose (Dmean), whole lung V20Gy, whole lung mean dose (Dmean), right (Rt.) breast mean dose (Dmean), and Rt. lung mean dose (Dmean) were evaluated.

To evaluate the delivery time, the actual beam-on time was compared between the DL-MLC and VB-MLC plans for 15 patients.

2.5 Statistical evaluation

The Wilcoxon signed-rank test, which is a nonparametric statistical hypothesis test, was used to compare the two treatment plans, corresponding to the Halcyon™ and VitalBeam® systems, for matched patients.

3 RESULTS

3.1 Analysis with isodose distribution and DVH

The dose distributions in the axial, coronal, and sagittal planes for the DL-MLC and VB-MLC plans are shown in Figure 1 (Patient 6). More doses were generated for the VB-MLC plan than for the DL-MLC plan. The isodose lines correspond to 110% (blue), 105% (red), 100% (orange), 95% (cyan), 90% (dark green), 70% (yellow), 50% (green), 30% (purple), 20% (blue), and 15% isodose (light blue).

Figure 2 shows the average dose–volume histogram (DVH) of the 15 left-sided breast cancer patients for the target volumes and OARs. The solid line and shaded bands represent the average and min–max range of the DVHs across all 15 patients in the planning study.

3.2 Analysis of plan quality and delivery time between DL-MLC and VB-MLC plans

Figure 3 and Table 4 show the results of the plan quality evaluation index for comparison between the DL-MLC and VB-MLC plans. Considering targets, DL-MLC plans had similar target coverage compared with VB-MLC plans, and there was no significant difference in the QC (0.881 ± 0.076, 0.849 ± 0.075), HI (1.308 ± 0.016, 1.311 ± 0.027), and CI (0.997 ± 0.001, 0.996 ± 0.003) between the DL-MLC plans and VB-MLC plans (p > 0.05).
**FIGURE 1** Dose distributions for the example case of comparison between dual-layer MLC (DL-MLC) and Millennium 120 MLC (VB-MLC) plans for early-stage left-sided breast cancer. Representative isodose distributions of the DL-MLC plan in (a) axial, (b) coronal, and (c) sagittal plane. Representative isodose distributions of the VB-MLC plan in (d) axial, (e) coronal, and (f) sagittal plane. The blue, red, orange, cyan, dark green, yellow, green, purple, blue, and light blue isodose lines represent 110%, 105%, 100%, 95%, 90%, 70%, 50%, 30%, 20%, and 15% isodose, respectively.

**FIGURE 2** Average dose–volume histogram (DVH) for the target volumes and the main organs at risk (OARs) for the left-sided breast cancer patients. The solid line and shaded bands represent the average and min–max range of the DVHs across all 15 patients in the planning study.

$V_{30Gy}$ and $D_{\text{mean}}$ for the heart were significantly lower in the DL-MLC plans than in the VB-MLC plans ($V_{30Gy} = 0.256\% \pm 0.498\%, 0.746\% \pm 6.97\%$, $p < 0.001$, $D_{\text{mean}} = 549.024 \pm 61.894, 642.656 \pm 65.445$ cGy, $p < 0.001$). The $D_{\text{mean}}$ value for the ipsilateral lung was significantly lower in the DL-MLC plans than in the VB-MLC plans ($D_{\text{mean}} = 949.088 \pm 74.144, 1004.416 \pm 74.652$ cGy, $p < 0.001$). $V_{20Gy}$ and $D_{\text{mean}}$ of the whole lung were significantly lower in the DL-MLC plans than in the VB-MLC plans ($V_{20Gy} = 5.065\% \pm 0.888\%$,
5.823 ± 1.060%, \( p = 0.010 \), \( D_{\text{mean}} = 621.376 \pm 42.687 \), 659.680 ± 39.908 cGy, \( p < 0.001 \). The \( D_{\text{mean}} \) values of the contralateral breast and contralateral lung for DL-MLC plans were lower than those for the VB-MLC plans (contralateral breast: 383.040 ± 72.563, 391.552 ± 83.361 cGy; contralateral lung: 340.480 ± 44.747, 353.248 ± 44.836 cGy). However, these differences are not statistically significant (\( p > 0.05 \)).

The delivery times are compared in Figure 4. Specifically, the delivery times for the DL-MLC and VB-MLC plans were 79 ± 10 and 101 ± 11 s, respectively. The average delivery time of DL-MLC was 27.8% lower than that of VB-MLC.

### DISCUSSION

In this study, to treat early-stage left-sided breast cancer, we compared the plan quality evaluations of DL-MLC and VB-MLC plans in terms of target coverage and OAR sparing. We found that the DL-MLC plans led to some improvement in OAR sparing. Furthermore, it is
presumed that the differences in the MLC configuration between the two MLC systems induced dosimetric differences in the OARs.

The leaf size of the novel staggered DL-MLC in Halcyon™ (1 cm) was larger than that of the Millennium 120-leaf MLC in VitalBeam® (0.5 cm). Furthermore, the DL-MLC entails less 6-MV-FFF transmission compared with the Millennium 120-leaf MLC (0.01% and 1.36%, respectively). The DLG is 0.01 mm in the DL-MLC, in contrast to the 0.5-mm DLG in the Millennium 120-leaf MLC. Thus, recent studies focused on the impact of MLC parameters on plan quality. Li et al. compared DL-MLC plans to Millennium 120-leaf MLC plans for nine patients with head and neck cancer. Compared with the Millennium 120-leaf MLC plans for IMRT, the DL-MLC plans exhibited improved OAR sparing regarding mean doses to the esophagus and larynx (p < 0.01, p = 0.03, respectively). Furthermore, the DL-MLC plans demonstrated marginal OAR sparing for the left and right cochlea (p = 0.06, p = 0.06, respectively). In another study, Li et al. compared the Halcyon™ DL-MLC to the Millennium 120-leaf MLC with Trilogy for 30 cervical carcinoma patients. For the PTVs, the two plans were comparable in terms of D2%, D98%, HI, CI, and the gradient index. However, V40Gy to the bladder was significantly different between the DL-MLC plans and Millennium 120-leaf MLC plans (24.37% ± 6.87% and 28.41% ± 7.62%, respectively; p = 0.001). In our study, the two plans (DL-MLC and VB-MLC) were comparable in terms of QC, CI, and HI for the PTVs. The V30Gy value of the heart and V20Gy of the whole lung in the DL-MLC plan were significantly lower than those in the VB-MLC plan (V30Gy = 0.256% ± 0.498% and 0.746% ± 0.697%, respectively; p < 0.001; V20Gy = 5.065% ± 0.888% and 5.823% ± 1.060%, respectively; p = 0.010).

Some studies have compared dosimetric differences between plans of breast cancer with those of Halcyon™ and other conventional linac. Sun et al. compared the dosimetric difference between different arc plans with Halcyon™ and Trilogy, with the prescription dose of 50 Gy per 25 fractions to the PTV. For the heart, Halcyon™ 4arc-plans reduced the V30Gy value; however, Dmean increased compared with Trilogy 8arc-plans (V30Gy = 0.8% ± 0.5%, 1.8 ± 1.7%; Dmean = 5.6 ± 0.6, 3.9 ± 1.1 Gy). Dmean of the lungs significantly increased for Halcyon™ 4arc-plans compared with Trilogy 8arc-plans (Dmean = 9.1% ± 0.8%, 7.5% ± 1.0%). Morris et al. compared the dosimetric difference between Halcyon™ plans and TruBeam plans, for a prescription dose of either 4256 cGy per 16 fractions or 5040 cGy per 28 fractions to the PTV. Dmean of the heart increased for Halcyon™ field-in-field plans compared with TrueBeam field-in-field plans (Dmean = 149.58 ± 129.01, 97.96 ± 78.27 cGy). However, Dmean of the ipsilateral lung decreased for Halcyon™ field-in-field plans compared with TrueBeam field-in-field plans (Dmean = 569.44 ± 221.73, 676.34 ± 175.84 cGy). In our study, V30Gy and Dmean of the heart significantly reduced for the Halcyon™ 2arc-plans compared with 2arc VitalBeam® plans (V30Gy = 0.256% ± 0.498%, 0.746% ± 0.697%, p < 0.001; Dmean = 549.024 ± 61.894, 642.656 ± 65.445 cGy, p < 0.001). Moreover, there were significant differences in Dmean of the ipsilateral lung between the DL-MLC and VB-MLC plans (949.088 ± 74.144 and 1004.416 ± 74.652 cGy). Statistically significant differences were found in the Dmean and V20Gy values of the whole lungs between the DL-MLC plans and VB-MLC plans (949.088 ± 74.144 and 1004.416 ± 74.652 cGy). Statistically significant differences were found in the Dmean and V20Gy values of the whole lungs between the DL-MLC plans and VB-MLC plans (949.088 ± 74.144 and 1004.416 ± 74.652 cGy). Statistically significant differences were found in the Dmean and V20Gy values of the whole lungs between the DL-MLC plans and VB-MLC plans (949.088 ± 74.144 and 1004.416 ± 74.652 cGy).

Radiotherapy for early-stage breast cancer reduces the rate of recurrence and death. However, this regimen can lead to an increased risk of ischemic heart disease via incidental irradiation of the heart. The rates of major coronary events increased by 7.4% per Gy increase in the mean dose to the heart. Additionally, the risk of major coronary events increased by 6.4% per Gy increase in the mean dose to the heart. In our study, the mean dose to the heart in the DL-MLC plan was significantly reduced by 14.6%, compared with that in the VB-MLC plan (549.024 ± 61.894 and 642.656 ± 65.445 cGy, respectively; p < 0.001). Therefore, for left-sided
breast cancer, the risk of heart toxicity is decreased in the case of treatment based on the DL-MLC plan.

5 | CONCLUSION

In this study, we compared the plan quality between the DL-MLC and VB-MLC plans. While there were differences in mechanical characteristics (i.e., lower transmission, lower DLG, faster gantry speed, and faster collimator speed), DL-MLC plans exhibited improved OAR sparing. In particular, when treating left-sided breast cancer via DL-MLC plans, the risk of heart toxicity is expected to be reduced.

ACKNOWLEDGMENTS

CONFLICT OF INTEREST

No conflicts of interest exist. This study had no sponsor involvement.

AUTHOR CONTRIBUTIONS

Conceived and designed the analysis: EBJ, SL. Collected the data: EBJ. Performed the analysis: CGP, MK. Validation: KHK, JBS, YJP, NKL, CYK. Wrote the draft paper: EJH. Supervision: SL. Writing-review & editing: KHK, JBS, YJP, NKL, CYK. Final approval of the version to be published: all authors.

ORCID

Kwang Hyeon Kim https://orcid.org/0000-0003-0434-1905
Suk Lee https://orcid.org/0000-0002-3720-3448

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Narod S, Iqbal J, Miller A. Why have breast cancer mortality rates declined? J Cancer Policy. 2015;5:8-17. https://www.sciencedirect.com/science/article/pii/S2213538315000065
3. Group EBCTC. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716.
4. Kim MM, Kennedy C, Scheuermann R, Freedman G, Li T. Whole breast and lymph node irradiation using HalcyonTM 2.0 utilizing automatic multi-isocenter treatment delivery and daily kilovoltage cone-beam computed tomography. Curesus. 2019;11(5):e4744.
5. Bartelink H, Horiot J-C, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259-3265.
6. Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer—a study based on the EORTC trial 22881–10882 boost versus no boost. Eur J Cancer. 2008;44(17):2587-2599.
7. Alford SL, Prassas GN, Vogelangs CR, Leggett HJ, Hamilton CS. Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives. J Med Imaging Radiat Oncol. 2013;57(2):222-229.
8. Katsochi D. Radiation therapy with a simultaneous integrated boost. Radiotherapy. 2017;123-141. https://www.intechopen.com/chapters/54069
9. Balaji K, Subramanian B, Yadav P, Radha CA, Ramasubramaniam V. Radiation therapy for breast cancer: literature review. Med Dosim. 2016;41(3):253-257.
10. Aznar MC, Duane FK, Darby SC, Wang Z, Taylor CW. Exposure of the lungs in breast cancer radiotherapy: a systematic review of lung doses published 2010–2015. Radiother Oncol. 2018;126(1):148-154.
11. Lind PA, Marks LB, Jamieson TA, et al. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue. Cancer. 2002;94(11):2821-2829.
12. Omari N, Thanopoulos E, Johnston SR. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat. 2014;146(2):245-258.
13. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998.
14. Jacobsen JN, Duane FK, Boekel NB, et al. Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys. 2019;103(3):595-604.
15. Brownlee Z, Garg R, Listo M, Zavitsanos P, Wazer DE, Huber KE. Late complications of radiation therapy for breast cancer: evolution in techniques and risk over time. Gland Surg. 2018;7(4):371.
16. Li T, Scheuermann R, Lin A, et al. Impact of multi-leaf collimator parameters on head and neck plan quality and delivery: a comparison between halcyon® and truebeam® treatment delivery systems. Curesus. 2018;10(11):e6348.
17. Panda S, Swamidas J, Chopra S, et al. Treatment planning comparison of volumetric modulated arc therapy employing a dual-layer stacked multi-leaf collimator and helical tomotherapy for cervix uteri. Radiother Oncol. 2020;15(1):22.
18. Lim TY, Dragoević I, Hoffman D, Flores-Martínez E, Kim GY. Characterization of the HalcyonTM multileaf collimator system. J Appl Clin Med Phys. 2019;20(4):106-114.
19. Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114(1):3-10.
20. Sun T, Lin X, Zhang G, Qiu Q, Li C, Yin Y. Treatment planning comparison of volumetric modulated arc therapy with the trilayer stacked multi-leaf collimator and helical tomotherapy for cervix uteri. Radiother Oncol. 2018;126(1):148-154.
21. Morris R, Laugeman E, Hilliard J, et al. Field-in-field breast planning for a jawless, double-stack MLC LINAC using flattening-filter free beams. J Appl Clin Med Phys. 2019;20(11):14-26.
22. Feuvret L, Noël G, Mazeron J-J, Bey P. Conformity index: a review. J Med Imaging Radiat Oncol. 2019;63(4):318-324.
23. Lee S, Cao YJ, Kim CY. Physical and radiobiological evaluation of radiotherapy treatment plan. In: Nenoi M, ed. Evolution of Ionizing Radiation Research Rijeka. Croatia: InTech; 2015:109-150. https://www.intechopen.com/chapters/49039

How to cite this article: Ju E, Heo EJ, Park CG, et al. Dosimetric comparison of VitalBeam® and HalcyonTM 2.0 for hypofractionated VMAT with simultaneous integrated boost treatment of early-stage left-sided breast cancer. J Appl Clin Med Phys. 2021;22:232-238. https://doi.org/10.1002/acm2.13428